Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inspire Medical Systems, Inc.INSP · Entity 1186 | Chief Operating Officer | February 09, 2024 | February 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inspire Medical Systems, Inc.
Report date February 09, 2024 · Filed February 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,027 |
Reported balance
After 2024-02-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-02-09 · Grant · Acquired 2,694 · Balance 3,027 F1: Represents an award of restricted stock units, which vests in three equal annual installments commencing on February 9, 2025. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2: Includes (i) 58 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "Plan") on June 30, 2023 and (ii) 32 shares acquired under the Plan on December 31, 2023. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.87 · Expires 2034-02-09 | Direct | 4,376 |
Reported balance
After 2024-02-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-09 · Grant · Acquired 4,376 · Balance 4,376 F3: The option vests and becomes exercisable as to 25% of the underlying shares on February 9, 2025. The remaining 75% of the underlying shares will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units, which vests in three equal annual installments commencing on February 9, 2025. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F2: Includes (i) 58 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "Plan") on June 30, 2023 and (ii) 32 shares acquired under the Plan on December 31, 2023.
F3: The option vests and becomes exercisable as to 25% of the underlying shares on February 9, 2025. The remaining 75% of the underlying shares will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ST JUDE MEDICAL, LLC
Report date January 04, 2017 · Filed January 06, 2017
Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 1
1 source rowRow 1 · 2017-01-04 · Disposition to issuer · Disposed 3,113 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.96 · Expires 2019-12-12 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-04 · Disposition to issuer · Disposed 3,333 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2020-12-10 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-04 · Disposition to issuer · Disposed 11,264 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-12-10 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-01-04 · Disposition to issuer · Disposed 8,799 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.08 · Expires 2022-12-08 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-01-04 · Disposition to issuer · Disposed 12,740 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.62 · Expires 2023-12-07 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-01-04 · Disposition to issuer · Disposed 34,376 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-01-04 · Disposition to issuer · Disposed 502 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-01-04 · Disposition to issuer · Disposed 938 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-01-04 · Disposition to issuer · Disposed 2,736 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2024 Filed Feb 14, 2024 02:46 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,376 | $0.00 Strike: $194.87 | $0.00 |
DisclosureSEC source: 0001104659-24-022573 · tm245999-6_4seq1.xml · derivative · entry 2 Ebeling Philip · CIK 0001662781 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,376 Underlying: Common Stock · 4,376 shares Expires 2034-02-09 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on February 9, 2025. The remaining 75% of the underlying shares will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 02:46 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 2,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-022573 · tm245999-6_4seq1.xml · nonDerivative · entry 1 Ebeling Philip · CIK 0001662781 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,027 F1 · shares: Represents an award of restricted stock units, which vests in three equal annual installments commencing on February 9, 2025. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · balance_after: Includes (i) 58 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "Plan") on June 30, 2023 and (ii) 32 shares acquired under the Plan on December 31, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:54 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $194.82 | $0.00 |
DisclosureSEC source: 0001104659-23-023901 · tm237460-1_4seq1.xml · derivative · entry 3 Ebeling Philip · CIK 0001662781 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,300 Underlying: Common Stock · 7,000 shares Expires 2030-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option has vested and became exercisable as to 25% of the underlying shares on the first anniversary of December 14, 2020 and the remaining 75% of the underlying shares have vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:54 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | SaleCommon Stock | 7,000 | $275.00 | $1,925,000.00 |
DisclosureSEC source: 0001104659-23-023901 · tm237460-1_4seq1.xml · nonDerivative · entry 2 Ebeling Philip · CIK 0001662781 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:54 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | Exercise / conversionCommon Stock | 7,000 | $194.82 | $1,363,740.00 |
DisclosureSEC source: 0001104659-23-023901 · tm237460-1_4seq1.xml · nonDerivative · entry 1 Ebeling Philip · CIK 0001662781 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 01:00 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantEmployee Stock Option (Right to Buy) · Derivative | 5,450 | $0.00 Strike: $263.16 | $0.00 |
DisclosureSEC source: 0001104659-23-022085 · tm236006-9_4seq1.xml · derivative · entry 2 Ebeling Philip · CIK 0001662781 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,450 Underlying: Common Stock · 5,450 shares Expires 2033-02-10 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of February 10, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| November 18, 2022 Filed Feb 15, 2023 01:00 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GiftCommon Stock | 167 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-022085 · tm236006-9_4seq1.xml · nonDerivative · entry 1 Ebeling Philip · CIK 0001662781 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243 F1 · balance_after: Reflects (a) (i) 167 shares acquired under the Inspire Medical Systems, Inc. (the "Company") 2018 Employee Stock Purchase Plan (the "ESPP") on December 31, 2020, (ii) 81 shares acquired under the ESPP on June 30, 2021, (iii) 51 shares acquired under the ESPP on December 31, 2021, (iv) 80 shares acquired under the ESPP on June 30, 2022 and (v) 31 shares acquired under the ESPP on December 31, 2022, minus (b) the 167 shares gifted on November 18, 2022. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:31 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantEmployee Stock Option (Right to Buy) · Derivative | 5,924 | $0.00 Strike: $227.53 | $0.00 |
DisclosureSEC source: 0001104659-22-023821 · tm226817-2_4seq1.xml · derivative · entry 1 Ebeling Philip · CIK 0001662781 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,924 Underlying: Common Stock · 5,924 shares Expires 2032-02-11 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of Feruary 11, 2022 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:56 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,300 | $0.00 Strike: $194.82 | $0.00 |
DisclosureSEC source: 0001104659-20-136414 · a4.xml · derivative · entry 1 Ebeling Philip · CIK 0001662781 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,300 Underlying: Common Stock · 17,300 shares Expires 2030-12-14 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of December 14, 2020 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 20:17 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $87.02 | $0.00 |
DisclosureSEC source: 0001104659-20-079720 · a4.xml · derivative · entry 1 Ebeling Philip · CIK 0001662781 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of June 30, 2020 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:14 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 2,736 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000590 · edgar.xml · derivative · entry 9 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,736 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:14 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 34,376 | Not disclosed Strike: $61.62 | Not disclosed |
DisclosureSEC source: 0001179110-17-000590 · edgar.xml · derivative · entry 8 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,376 shares Expires 2023-12-07 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:14 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000590 · edgar.xml · derivative · entry 7 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 938 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:14 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 12,740 | Not disclosed Strike: $69.08 | Not disclosed |
DisclosureSEC source: 0001179110-17-000590 · edgar.xml · derivative · entry 6 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,740 shares Expires 2022-12-08 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:14 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 502 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000590 · edgar.xml · derivative · entry 5 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 502 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:14 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 8,799 | Not disclosed Strike: $59.41 | Not disclosed |
DisclosureSEC source: 0001179110-17-000590 · edgar.xml · derivative · entry 4 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,799 shares Expires 2021-12-10 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:14 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 11,264 | Not disclosed Strike: $35.27 | Not disclosed |
DisclosureSEC source: 0001179110-17-000590 · edgar.xml · derivative · entry 3 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,264 shares Expires 2020-12-10 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:14 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 3,333 | Not disclosed Strike: $34.96 | Not disclosed |
DisclosureSEC source: 0001179110-17-000590 · edgar.xml · derivative · entry 2 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2019-12-12 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:14 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerCommon Stock | 3,113 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000590 · edgar.xml · nonDerivative · entry 1 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock Units · Derivative | 912 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · derivative · entry 12 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,736 Underlying: Common Stock · 3,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock units · Derivative | 469 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · derivative · entry 11 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938 Underlying: Common Stock · 1,407 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock Units · Derivative | 502 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · derivative · entry 10 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502 Underlying: Common Stock · 1,004 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock Units · Derivative | 704 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · derivative · entry 9 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 704 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Tax withholdingCommon Stock | 307 | $79.20 | $24,314.40 |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · nonDerivative · entry 8 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,113 F5 · shares: 912 shares of restricted stock vested on December 17, 2016. 307 shares were used to pay taxes and 605 shares were released. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · nonDerivative · entry 7 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 158 | $79.20 | $12,513.60 |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · nonDerivative · entry 6 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: 469 shares of restricted stock vested on December 17, 2016. 158 shares were used to pay taxes and 311 shares were released. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 469 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · nonDerivative · entry 5 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Tax withholdingCommon Stock | 169 | $79.20 | $13,384.80 |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · nonDerivative · entry 4 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,197 F3 · shares: 502 shares of restricted stock vested on December 17, 2016. 169 shares were used to pay taxes and 333 shares were released. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 502 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · nonDerivative · entry 3 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Tax withholdingCommon Stock | 237 | $79.20 | $18,770.40 |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · nonDerivative · entry 2 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,864 F2 · shares: 704 shares of restricted stock vested on December 17, 2016. 237 shares were used to pay taxes and 467 shares were released. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 16:56 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033306 · edgar.xml · nonDerivative · entry 1 Ebeling Philip · CIK 0001662781 · VP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.